Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisBrian G. Feagan, Asit Parikh, Paul Rutgeerts et al.|New England Journal of Medicine|2013Cited by 2.9k
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trialLaurent Peyrin‐Biroulet, Peter Bossuyt, Young S. Oh et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 96
943b Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 TrialBrian G. Feagan, Aparna R. Parikh, P. J. Rutgeerts et al.|Gastroenterology|2012Cited by 43
Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 TrialBrian G. Feagan, Asit Parikh, Bruce E. Sands et al.|The American Journal of Gastroenterology|2012Cited by 17
Novel Microbial-Based Immunotherapy Approach for Crohn's DiseaseSimon Sutcliffe, Hal Gunn, Shirin Kalyan et al.|Frontiers in Medicine|2019Cited by 9